Results for tag: "Kainate Receptor Antagonist"

The Kainate Receptor Antagonist market is a subset of the Central Nervous System Drugs market. Kainate Receptor Antagonists are drugs that block the action of kainate receptors, which are glutamate receptors found in the brain and spinal cord. These drugs are used to treat a variety of neurological disorders, including epilepsy, anxiety, and depression. Kainate Receptor Antagonists are also being studied for their potential to treat Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Kainate Receptor Antagonists are typically administered orally or intravenously. They are generally well-tolerated, with few side effects. However, they can cause drowsiness, dizziness, and nausea in some patients. Several companies are involved in the Kainate Receptor Antagonist market, including AstraZeneca, GlaxoSmithKline, Merck, Pfizer, and Sanofi. These companies are researching and developing new Kainate Receptor Antagonists for the treatment of neurological disorders. Show Less Read more